Literature DB >> 21660494

Polycythemia vera: gender-related phenotypic differences.

Raffaele Landolfi1, Leonardo Di Gennaro, Maria Anna Nicolazzi, Igor Giarretta, RosaMaria Marfisi, Roberto Marchioli.   

Abstract

In polycythemia vera, gender has recently been shown to influence the JAK2(V617F) allele burden, but its effect on the disease phenotype is unknown. This issue was investigated using the database of the European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Study. The ECLAP Study recruited 1,638 polycythemic subjects and followed for 2.7 ± 1.3 years. At study entry, men, compared to women, had a higher prevalence of myocardial infarction (11.3 vs. 5.8%; P < 0.0001) and peripheral arterial disease (6.1 vs. 2.9%; P < 0.05) while a history of venous thrombosis was more common in women (11.4 vs. 7.9%, P = 0.016). Among 234 venous thrombosis, there were 39 splanchnic vein thromboses (33 extra-hepatic portal vein thromboses and 6 Budd-Chiari syndromes). Most of these events occurred as an early disease presentation in young female subjects. Women, compared to men, had higher platelet counts (average value 430 ± 213 vs. 375 ± 201 × 10(9)/L; P < 0.0001) and lower hematocrits (0.46 ± 0.06 vs. 0.48 ± 0.06 l/l; P < 0.0001). Cholesterol plasma level, available in 995 subjects (61%), was lower in male patients (180.8 ± 43.1 vs. 196 ± 46.6 mg/dl; P < 0.0001). During follow-up there were 205 major thromboses confirming an high incidence of myocardial infarction in men although not statistically significant (1.2 vs. 0.6 cases per 100 person-years; P > 0.05). These data show several gender-related differences both in the thrombotic diathesis and in the prevalence of vascular risk factors of PV patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660494     DOI: 10.1007/s11739-011-0634-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  30 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

3.  Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.

Authors:  U Berger; O Maywald; M Pfirrmann; T Lahaye; A Hochhaus; A Reiter; J Hasford; H Heimpel; D K Hossfeld; H-J Kolb; H Löffler; H Pralle; W Queisser; R Hehlmann
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

4.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Authors:  Guido Finazzi; Alessandro Rambaldi; Vittoria Guerini; Alessandra Carobbo; Tiziano Barbui
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

5.  Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.

Authors:  Sylvie Tondeur; Sandrine Boutruche; Christine Biron-Andréani; Jean-François Schved
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

6.  Gender differences in survival in advanced heart failure. Insights from the FIRST study.

Authors:  K F Adams; C A Sueta; M Gheorghiade; C M O'Connor; T A Schwartz; G G Koch; B Uretsky; K Swedberg; W McKenna; J Soler-Soler; R M Califf
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

7.  Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.

Authors:  Yasmine Chait; Bertrand Condat; Dominique Cazals-Hatem; Pierre Rufat; Sai Atmani; Driss Chaoui; Françoise Guilmin; Jean Jacques Kiladjian; Aurélie Plessier; Marie Hélène Denninger; Nicole Casadevall; Dominique Valla; Jean B Brière
Journal:  Br J Haematol       Date:  2005-05       Impact factor: 6.998

8.  Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.

Authors:  Brady L Stein; Donna M Williams; Nae-Yuh Wang; Ophelia Rogers; Mary Ann Isaacs; Naveen Pemmaraju; Jerry L Spivak; Alison R Moliterno
Journal:  Haematologica       Date:  2010-02-04       Impact factor: 9.941

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Chiara M Dellacasa; Silvia Salmoiraghi; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Exp Hematol       Date:  2009-06-24       Impact factor: 3.084

View more
  8 in total

Review 1.  New Therapeutic Approaches in Polycythemia Vera.

Authors:  Lorenzo Falchi; Kate J Newberry; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

2.  Polycythemia Rubra Vera and Sporadic Bilateral Renal Angiomyolipomas: A Case Report.

Authors:  James C Barton; Barrett P Cary; Robert M Frederickson
Journal:  Cureus       Date:  2022-04-11

3.  MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.

Authors:  Huichun Zhan; Christopher Cardozo; Wayne Yu; Antai Wang; Alison R Moliterno; Chi V Dang; Jerry L Spivak
Journal:  Blood Cells Mol Dis       Date:  2012-12-21       Impact factor: 3.039

Review 4.  Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.

Authors:  Eikan Mishima; Takehiro Suzuki; Yoichi Takeuchi; Kazumasa Seiji; Noriko Fukuhara; Kei Takase; Hideo Harigae; Takaaki Abe; Sadayoshi Ito
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-14       Impact factor: 3.738

5.  Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Elisa Bonetti; Rita Campanelli; Adriana Carolei; Paolo Catarsi; Antonina M Isgrò; Letizia Lupo; Margherita Massa; Valentina Poletto; Gianluca Viarengo; Laura Villani; Umberto Magrini
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

6.  Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.

Authors:  Niloofar Allahverdi; Mohamed Yassin; Mohamed Ibrahim
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Lights Off, Lights On: Amaurosis Fugax in Polycythemia.

Authors:  Shao Sze Tan; Amir Samsudin; Lakana Kumar Thavaratnam; Masnon Nurul-Ain
Journal:  Cureus       Date:  2022-06-08

Review 8.  Is there a gender effect in polycythemia vera?

Authors:  Francesca Palandri; Barbara Mora; Naseema Gangat; Lucia Catani
Journal:  Ann Hematol       Date:  2020-10-02       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.